Total VTE · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL)
Statin probably leads to lower all cases of VTE compared with placebo (moderate certainty).
1 finding from 1 review
Pulmonary embolism · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL)
1 finding from 1 review
Deep vein thrombosis · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL)
1 finding from 1 review
Any MI · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL)
Statin probably leads to lower any MI compared with placebo (moderate certainty).
1 finding from 1 review
Stroke · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL)
Statin probably leads to lower any stroke compared with placebo (moderate certainty).
1 finding from 1 review
Death · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL)
Statin probably leads to lower death compared with placebo (moderate certainty).
1 finding from 1 review
Any serious adverse event · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL)
Statin showed no clear difference in any serious adverse event compared with placebo (moderate certainty).
1 finding from 1 review
Intraoperative blood loss (mL) · people with PAD undergoing MLLA
1 finding from 1 review
Fall in haemoglobin levels(g/L or mmol/L) ( · people with PAD undergoing MLLA
1 finding from 1 review
Blood transfusion · people with PAD undergoing MLLA
1 finding from 1 review
Primary wound‐healing rates (6 weeks) · people with PAD undergoing MLLA
1 finding from 1 review
Stump revision rates (maximal · people with PAD undergoing MLLA
1 finding from 1 review
Postoperative complications (maximal · people with PAD undergoing MLLA
1 finding from 1 review
Postoperative mortality (6 weeks) · people with PAD undergoing MLLA
1 finding from 1 review
All‐cause mortality ( · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy
It is very uncertain whether intramuscular injection of bone marrow mononuclear cells (BMMNC) changes all‐cause mortality ( compared with control (very low certainty).
1 finding from 1 review
Reduction in pain Various scales including VAS, PISQ; scales ranged from 0 to 4/10/100, where 0 = no pain ( · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy
1 finding from 1 review
Amputation · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy
It is very uncertain whether intramuscular injection of bone marrow mononuclear cells (BMMNC) changes incidence of amputation ( compared with control (very low certainty).
1 finding from 1 review
Angiographic analysis · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Increase in ABI An ABI ratio of 0.9 or less indicates PAD. Values between 0.9 and 1.0 are borderline, and above 1.0 is considered normal ( · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy
1 finding from 1 review
Increase in PFWD (m) ( · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy
1 finding from 1 review